A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Burns, Michael C.
Sagar, Vinay
Jovanovic, Borko
Morgans, Alicia K.
VanderWeele, David James
Quinn, David I.
Stadler, Walter Michael
Abdulkadir, Sarki
Hussain, Maha H. A.
机构：
[1] Northwestern Univ, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA
[4] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[5] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[6] Univ Chicago, Chicago, IL 60637 USA
[7] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS274
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
    Jensen, A.
    Karunaratna, N.
    Wong, S.
    Shapiro, J.
    Weickhardt, A.
    Spain, L.
    Azad, A. A.
    Kwan, E.
    Muthusamy, A.
    Torres, J.
    Parente, P.
    Francis, P.
    Parnis, F. X.
    Goh, J.
    Gibbs, P.
    Tran, B.
    Anton, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1329 - S1330
  • [22] Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Adesunloye, Bamidele
    Huang, Xuan
    Ning, Yangmin M.
    Madan, Ravi A.
    Gulley, James L.
    Beatson, Melony
    Kluetz, Paul Gustav
    Adelberg, David
    Arlen, Philip M.
    Parnes, Howard L.
    Mulquin, Marcia
    Steinberg, Seth M.
    Wright, John Joseph
    Trepel, Jane B.
    Dawson, Nancy Ann
    Chen, Clara
    Apolo, Andrea Borghese
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [23] Docetaxel rechallenge chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).
    Bracarda, S.
    Sisani, M.
    Rossi, M.
    Galli, L.
    Hamzaj, A.
    Scali, S.
    De Angelis, V.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Dorff, Tanya B.
    Quinn, David, I
    Pinski, Jacek K.
    Goldkorn, Amir
    Sadeghi, Sarmad
    Tsao-Wei, Denice
    Groshen, Susan
    Kuhn, Peter
    Gross, Mitchell E.
    CLINICAL GENITOURINARY CANCER, 2019, 17 (04) : 241 - +
  • [25] FDG and PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
    Zukotynski, Katherine A.
    Jadvar, Hossein
    Cho, Steve Y.
    Kim, Chun Ki
    Cline, Kathryn
    Emmenegger, Urban
    Hotte, Sebastien J.
    Pond, Gregory Russell
    Winquist, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [26] Cabazitaxel for octogenarian patients with metastatic castration-resistant prostate cancer (MCRPC)
    Tralongo, P.
    Bordonaro, S.
    Di Lorenzo, G.
    Borsellino, N.
    Facchini, G.
    Rossetti, S.
    Martelli, V.
    Longo, V.
    Tralongo, A. C.
    Caspani, F.
    Tuzi, A.
    Spada, M.
    Calvani, N.
    Carlini, P.
    De Giorgi, U. F. F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
    Karunaratna, Nathasha
    Jensen, Andrew
    Wong, Shirley
    Shapiro, Julia
    Weickhardt, Andrew
    Spain, Lavinia
    Azad, Arun
    Kwan, Edmond M.
    Muthusamy, Arun
    Torres, Javier
    Parente, Phillip
    Parnis, Francis
    Goh, Jeffrey
    Gibbs, Peter
    Tran, Ben
    Anton, Angelyn
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 58 - 58
  • [28] Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Henriquez, Ivan
    Roach, Mack I. I. I. I. I. I.
    Morgan, Todd M.
    Bossi, Alberto
    Gomez, Junior A.
    Abuchaibe, Oscar
    Counago, Felipe
    BIOMEDICINES, 2021, 9 (09)
  • [29] Phase-II-Studie bei Patienten mit metastasiertem kastrationsresistenten Prostatakarzinom (mCRPC)Phase II study with metastatic castration-resistant prostate cancer (mCRPC) patients
    H. Rexer
    M. Graefen
    Der Urologe, 2017, 56 (11): : 1468 - 1470
  • [30] A Phase II Study of the Dual mTOR Inhibitor MLN0128 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
    Rathkopf, Dana E.
    Slovin, Susan F.
    Autio, Karen A.
    Delacrur, Anthony
    Shelkey, Gregory
    Pisano, Katherine
    Hullings, Melanie
    DeNunzio, Mia
    Morris, Michael J.
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345